Home/Filings/4/0001144204-19-000790
4//SEC Filing

McBarron Paul 4

Accession 0001144204-19-000790

CIK 0001130166other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 9:28 AM ET

Size

10.6 KB

Accession

0001144204-19-000790

Insider Transaction Report

Form 4
Period: 2019-01-03
McBarron Paul
DirectorEVP, Finance, CFO, COO
Transactions
  • Award

    Option

    2019-01-04+270,079270,079 total
    Exercise: $0.71Exp: 2029-01-04Common Stock (270,079 underlying)
  • Award

    Option

    2019-01-03+13,02113,021 total
    Exercise: $1.74Exp: 2027-12-29Common Stock (13,021 underlying)
  • Award

    Option

    2019-01-03+11,98011,980 total
    Exercise: $1.56Exp: 2028-02-22Common Stock (11,980 underlying)
Footnotes (4)
  • [F1]These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
  • [F2]These securities were granted as part of the Issuer's annual compensation review to executive officers.
  • [F3]On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares.
  • [F4]On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares.

Issuer

Cyclacel Pharmaceuticals, Inc.

CIK 0001130166

Entity typeother

Related Parties

1
  • filerCIK 0001357397

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 9:28 AM ET
Size
10.6 KB